Recently,the CCID Consulting,a subsidiary of the China Center for Information Industry Development(CCID),under the Ministry of Industry and Information Technology（MIIT),released the“2023 Top 100 National Biopharmaceutical Industry Parks”list.Wuqing Development Zone ranked 34th,marking a significant improvement of 14 places compared to the previous year and achieving a breakthrough.This is the fourth annual release of this list by CCID Consulting,and Wuqing Development Zone has consecutively made the list for four years.
It is understood that this year’s list is guided by the new requirements of the 20th National Congress of the Communist Party of China,with the aim of guiding the direction of industrial development and promoting the high-quality development of China’s biopharmaceutical industry.The evaluation system,based on the“Six-Dimensional Model”,has been further expanded and optimized to the“Three Forces and Three Transformations”model.It comprehensively assesses the strength of the biopharmaceutical industry in 176 national-level high-tech zones(excluding Suzhou Industrial Park)and 230 national-level economic development zones(as of 2022)across six dimensions:basic strength,enterprise cohesion,business attraction,high-end development,intelligence,and greenness,ultimately forming the top 100 list.
Wuqing Development Zone regards the biopharmaceutical industry as its leading industry.Leveraging existing resources such as the International Health Industry Technology Research Institute,International Health Industry Park,and Synthetic Biology Industry Fund,it vigorously creates a favorable industrial ecosystem where resource elements gather at an accelerated pace.This has resulted in an industrial cluster primarily focused on pharmaceuticals,medical devices,precision medicine,medical big data,and synthetic biology.To date,it has attracted more than 240 high-quality biopharmaceutical companies,including Chase Sun Pharmaceutical,BMC Medical,Novogene,GensKey,Turing Health,Unibio,and Tsingke Biotech.
In the next step,Wuqing Development Zone will expedite the construction of the National Key Laboratory for Synthetic Biology and industrial bases,establish the Beijing-Tianjin-Hebei Synthetic Biology Industry Alliance,and accelerate the development of platforms such as GLP Experimental Animal Centers,artificial cell factories,and full-process automation in biopharmaceuticals.With synthetic biology technology as its core advantage,it will extend its development into precision diagnostic technologies,biopharmaceutical outsourcing services,and other biotechnologies.This will radiate and drive the development of the biopharmaceutical industry,forming a“point-line-surface-body”biopharmaceutical industry cluster.
News 
Contact Us
Home